Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: Clinical and molecular analyses of a phase 3 study

American Journal of Hematology

Volumn 89, Issue 12, 2014, Pages 1085-1091

  Tacchetti, Paola ^a   Terragna, Carolina ^a   Galli, Monica ^b   Zamagni, Elena ^a   Petrucci, Maria Teresa ^c   Pezzi, Annalisa ^a   Montefusco, Vittorio ^d   Martello, Marina ^a   Tosi, Patrizia ^e   Baldini, Luca ^f   Peccatori, Jacopo ^g   Ruggieri, Miriana ^h   Pantani, Lucia ^a   Lazzaro, Antonio ⁱ   Elice, Francesca ^j   Rocchi, Serena ^a   Gozzetti, Alessandro ^k   Cavaletti, Guido ^l   Palumbo, Antonio ^m   Cavo, Michele ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b OSPEDALI RIUNITI   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d NATIONAL CANCER INSTITUTE   (Italy)

^e Ospedale di Rimini   (Italy)

^f FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^g SAN RAFFAELE HOSPITAL   (Italy)

^h SC Ematologia Ospedale C G Mazzoni   (Italy)

ⁱ Azienda USL di Piacenza   (Italy)

^j SAN BORTOLO HOSPITAL   (Italy)

^k UNIVERSITY OF SIENA   (Italy)

^l UNIVERSITY OF MILANO BICOCCA   (Italy)

^m CITTÀ DELLA SALUTE E DELLA SCIENZA HOSPITAL   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; THALIDOMIDE; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; PYRAZINE DERIVATIVE; SDC1 PROTEIN, HUMAN; SYNDECAN 1;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; AUTOTRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENE EXPRESSION PROFILING; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NERVOUS SYSTEM DEVELOPMENT; OVERALL SURVIVAL; PERIPHERAL BLOOD STEM CELL; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PLASMA CELL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; ACTIN FILAMENT; ADOLESCENT; BONE MARROW TRANSPLANTATION; CANCER GRADING; CHEMICALLY INDUCED; CLINICAL TRIAL; DRUG MONITORING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; MORTALITY; NERVE FIBER; PATHOLOGY; SURVIVAL;

ACTIN CYTOSKELETON; ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AXONS; BONE MARROW TRANSPLANTATION; BORONIC ACIDS; DEXAMETHASONE; DRUG MONITORING; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM GRADING; NEUROGENESIS; PERIPHERAL NERVOUS SYSTEM DISEASES; PLASMA CELLS; PYRAZINES; SURVIVAL ANALYSIS; SYNDECAN-1; THALIDOMIDE; TRANSPLANTATION, AUTOLOGOUS;

EID: 84908445489     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23835     Document Type: Article

References (53)

1. Dispenzieri A, Kyle RA. Neurological aspects of multiple myeloma and related disorders. Best Pract Res Clin Haematol 2005;18:673-688.
2. Plasmati R, Pastorelli F, Cavo M, et al. Neuropathy in multiple myeloma treated with thalidomide: A prospective study. Neurology 2007;69:573-581.
3. Chaudhry V, Cornblath DR, Polydefkis M, et al. Characteristics of bortezomib- and thalidomide-induced peripheral neuropathy. J Peripher Nerv Syst 2008;13:275-282.
4. Richardson PG, Xie W, Mitsiades C, et al. Single-agent bortezomib in previously untreated multiple myeloma: Efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J Clin Oncol 2009;27:3518-3525.
5. Cavaletti G, Jakubowiak AJ. Peripheral neuropathy during bortezomib treatment of multiple myeloma: A review of recent studies. Leuk Lymph 2010;51:1178-1187.
6. Richardson PG, Delforge M, Beksac M, et al. Management of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia 2012;26:595-608.
7. Delforge M, Blade J, Dimopoulos MA, et al. Treatment-related peripheral neuropathy in multiple myeloma: The challenge continues. Lancet Oncol 2010;11:1086-1095.
8. Rajkumar SV, Blood E, Vesole D, et al. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: A clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006;24:431-436.
9. Rajkumar SV, Rosinol L, Hussein M, et al. Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. J Clin Oncol 2008;26:2171-2177.
10. Palumbo A, Bringhen S, Caravita T, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: Randomised controlled trial. Lancet 2006;367:825-831.
11. Facon T, Mary JY, Hulin C, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): A randomised trial. Lancet 2007;370:1209-1218.
12. Hulin C, Facon T, Rodon P, et al. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. J Clin Oncol 2009;27:3664-3670.
13. Lokhorst HM, Schmidt-Wolf I, Sonneveld P, et al. Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma. Haematologica 2008;93:124-127.
14. Cavo M, Di Raimondo F, Zamagni E, et al. Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma. J Clin Oncol 2009;27:5001-5007.
15. Harousseau JL, Attal M, Avet-Loiseau H, et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: Results of the IFM 2005-01 phase III trial. J Clin Oncol 2010;28:4621-4629.
16. Reeder CB, Reece DE, Kukreti V, et al. Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: High response rates in a phase II clinical trial. Leukemia 2009;23:1337-1341.
17. Dimopoulos MA, Mateos MV, Richardson PG, et al. Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: Subanalysis of the phase 3 VISTA study. Eur J Haematol 2011;86:23-31.
18. Moreau P, Avet-Loiseau H, Facon T, et al. Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma. Blood 2011;118:5752-5758; quiz 5982.
19. Sonneveld P, Schmidt-Wolf IG, van der Holt B, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: Results of the randomized phase III HOVON-65/GMMG-HD4 trial. J Clin Oncol 2012;30:2946-2955.
20. Mohty B, El-Cheikh J, Yakoub-Agha I, et al. Peripheral neuropathy and new treatments for multiple myeloma: Background and practical recommendations. Haematologica 2010;95:311-319.
21. Giannini F, Volpi N, Rossi S, et al. Thalidomide-induced neuropathy: A ganglionopathy? Neurology 2003;60:877-878.
22. Azoulay D, Lavie D, Horowitz N, et al. Bortezomib-induced peripheral neuropathy is related to altered levels of brain-derived neurotrophic factor in the peripheral blood of patients with multiple myeloma. Br J Haematol 2014;164:454-456.
23. Cavaletti G, Gilardini A, Canta A, et al. Bortezomib-induced peripheral neurotoxicity: A neurophysiological and pathological study in the rat. Exp Neurol 2007;204:317-325.
24. Landowski TH, Megli CJ, Nullmeyer KD, et al. Mitochondrial-mediated disregulation of Ca2+ is a critical determinant of Velcade (PS-341/bortezomib) cytotoxicity in myeloma cell lines. Cancer Res 2005;65:3828-3836.
25. Casafont I, Berciano MT, Lafarga M. Bortezomib induces the formation of nuclear poly(A) RNA granules enriched in Sam68 and PABPN1 in sensory ganglia neurons. Neurotox Res 2010;17:167-178.
26. Ravaglia S, Corso A, Piccolo G, et al. Immune-mediated neuropathies in myeloma patients treated with bortezomib. Clin Neurophysiol 2008;119:2507-2512.
27. Poruchynsky MS, Sackett DL, Robey RW, et al. Proteasome inhibitors increase tubulin polymerization and stabilization in tissue culture cells: A possible mechanism contributing to peripheral neuropathy and cellular toxicity following proteasome inhibition. Cell Cycle 2008;7:940-949.
28. Cavaletti G, Marmiroli P. Chemotherapy-induced peripheral neurotoxicity. Nat Rev Neurol 2010;6:657-666.
29. Staff NP, Podratz JL, Grassner L, et al. Bortezomib alters microtubule polymerization and axonal transport in rat dorsal root ganglion neurons. Neurotoxicology 2013;39:124-131.
30. Broyl A, Corthals SL, Jongen JL, et al. Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: A prospective analysis of data from the HOVON-65/GMMG-HD4 trial. Lancet Oncol 2010;11:1057-1065.
31. Favis R, Sun Y, van de Velde H, et al. Genetic variation associated with bortezomib-induced peripheral neuropathy. Pharmacogenet Genom 2011;21:121-129.
32. Johnson DC, Corthals SL, Walker BA, et al. Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma. J Clin Oncol 2011;29:797-804.
33. Corthals SL, Kuiper R, Johnson DC, et al. Genetic factors underlying the risk of bortezomib induced peripheral neuropathy in multiple myeloma patients. Haematologica 2011;96:1728-1732.
34. Cavo M, Pantani L, Petrucci MT, et al. Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. Blood 2012;120:9-19.
35. Cavo M, Tacchetti P, Patriarca F, et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: A randomised phase 3 study. Lancet 2010;376:2075-2085.
36. Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998;102:1115-1123.
37. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609-2617.
38. Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia 2006;20:1467-1473.
39. Richardson PG, Sonneveld P, Schuster MW, et al. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: Impact of a dose-modification guideline. Br J Haematol 2009;144:895-903.
40. Ludwig H, Viterbo L, Greil R, et al. Randomized phase II study of bortezomib, thalidomide, and dexamethasone with or without cyclophosphamide as induction therapy in previously untreated multiple myeloma. J Clin Oncol 2013;31:247-255.
41. Rosinol L, Oriol A, Teruel AI, et al. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: A randomized phase 3 PETHEMA/GEM study. Blood 2012;120:1589-1596.
42. Ocio EM, Richardson PG, Rajkumar SV, et al. New drugs and novel mechanisms of action in multiple myeloma in 2013: A report from the International Myeloma Working Group (IMWG). Leukemia 2014;28:525-542.
43. Lok A, Mocquard J, Bourcier J, et al. Subcutaneous bortezomib incorporated into the bortezomib-thalidomide-dexamethasone regimen as part of front-line therapy in the context of autologous stem cell transplantation for multiple myeloma. Haematologica 2014;99:e33-34.
44. Brioli A, Zannetti BA, Zamagni E, et al. Peripheral neuropathy induced by subcutaneous bortezomib-based induction therapy for newly diagnosed multiple myeloma. Haematologica 2014;[Epub ahead of print]
45. van den Bent MJ, van Raaij-van den Aarssen VJ, Verweij J, et al. Progression of paclitaxel-induced neuropathy following discontinuation of treatment. Muscle Nerve 1997;20:750-752.
46. Richardson PG, Briemberg H, Jagannath S, et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 2006;24:3113-3120.
47. Ghobrial IM, Rajkumar SV. Management of thalidomide toxicity. J Support Oncol 2003;1:194-205.
48. Cavaletti G, Beronio A, Reni L, et al. Thalidomide sensory neurotoxicity: A clinical and neurophysiologic study. Neurology 2004;62:2291-2293.
49. Tosi P, Zamagni E, Cellini C, et al. Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma. Eur J Haematol 2005;74:212-216.
50. Velasco R, Petit J, Clapes V, et al. Neurological monitoring reduces the incidence of bortezomib-induced peripheral neuropathy in multiple myeloma patients. J Peripher Nerv Syst 2010;15:17-25.
51. Lanzani F, Mattavelli L, Frigeni B, et al. Role of a pre-existing neuropathy on the course of bortezomib-induced peripheral neurotoxicity. J Peripher Nerv Syst 2008;13:267-274.
52. Laser H, Mack TG, Wagner D, et al. Proteasome inhibition arrests neurite outgrowth and causes "dying-back" degeneration in primary culture. J Neurosci Res 2003;74:906-916.
53. Klimaschewski L, Hausott B, Ingorokva S, et al. Constitutively expressed catalytic proteasomal subunits are up-regulated during neuronal differentiation and required for axon initiation, elongation and maintenance. J Neurochem 2006;96:1708-1717.